Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data PTC THERAPEUTICS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
82.7
194
265
307
381
539
699
938
807
1,731
Cost of revenue
0
4.58
12.7
12.1
Gross profit
82.7
190
252
295
Research and development
118
117
172
257
478
541
651
667
534
455
Selling, general and administrative
97.1
121
154
203
245
286
326
333
301
347
General and administrative
97.1
121
Operating expenses
215
259
380
548
813
913
1,146
1,377
1,109
864
Operating income
-132
-64.3
-116
-241
-432
-374
-447
-440
-303
867
Other non-operating income
-1.21
-1.28
0.13
13.7
85.2
-57.9
-49.2
10.1
6.54
-18.1
Pre-tax income
-142
-77.7
-128
-240
-403
-518
-587
-696
-363
697
Income tax
0.57
1.34
-0.03
11.7
35.2
5.56
-28.5
-69.5
0.18
14
Net income
-142
-79
-128
-252
-438
-524
-559
-627
-363
683
EBITDA
-129
-46.6
-89.6
-209
-388
-310
-319
-203
-227
906
EPS, basic
-4.17
-2.02
-2.75
-4.27
-6.64
-7.43
-7.79
-8.37
-4.73
8.58
EPS, diluted
-4.17
-2.02
-2.75
-4.27
-6.64
-7.43
-7.79
-8.37
-4.73
7.78
Shares, basic (weighted)
34
39.2
46.6
58.9
66
70.5
71.7
74.8
76.8
79.5
Shares, diluted (weighted)
34
39.2
46.6
58.9
66
70.5
71.7
74.8
76.8
88.3
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
58.3
112
169
288
209
190
280
594
780
985
Short-term investments
173
79.5
58.1
399
895
584
131
283
360
961
Receivables
24.9
40.4
67.9
55.5
69.9
110
156
161
159
182
Inventory
0
10.8
16.1
19.3
18.7
15.9
21.8
30.6
23.2
79.6
Other current assets
4.69
6.67
9.25
17.9
39.5
54.7
106
150
44.1
67.3
Total current assets
261
249
321
779
1,232
954
694
1,219
1,366
2,274
Property, plant and equipment
7.43
8.38
12.7
21.5
33.8
52.6
72.6
87.1
61
55.4
Lease right-of-use assets
13.7
84.4
77.4
102
91.9
56.7
80.1
Goodwill
0
82.3
82.3
82.3
82.3
82.3
82.3
82.3
82.3
Intangible assets
0
133
701
711
715
725
706
379
119
389
Total assets
269
392
1,119
1,624
2,208
1,938
1,706
1,896
1,705
2,899
Accounts payable
6.3
15.3
6
10.3
18.7
23
27.3
6.05
17.3
45.5
Accrued liabilities
13.6
17.7
27.6
38.4
53.3
55.7
62.7
62.6
61.6
73.7
Deferred revenue
0
3.94
3.72
8.24
4.15
1.35
0.8
5.51
2.04
Short-term debt
0
11.7
20
150
287
Total current liabilities
49.6
82
167
236
277
509
406
603
581
968
Long-term debt
98.2
145
141
294
309
282
572
284
285
Lease liabilities
9.02
79.5
73.6
101
97.6
74.9
93.6
Other non-current liabilities
0.34
0.24
0.06
0.14
1.39
2.64
0.14
21.4
13.7
Total liabilities
150
235
768
1,029
1,726
1,937
2,053
2,714
2,803
3,104
Total debt
98.2
145
153
314
309
431
572
284
285
287
Paid-in capital
856
967
1,288
1,795
2,172
2,124
2,305
2,466
2,575
2,748
Retained earnings
-735
-814
-939
-1,190
-1,629
-2,098
-2,657
-3,284
-3,647
-2,964
Other comprehensive income
-1.49
3.97
1.46
-10.6
-61
-24.3
4.8
-1.29
-25.9
10.5
Shareholders' equity
120
156
351
594
482
1.44
-347
-819
-1,098
-205
Total equity
-1.49
156
351
594
482
1.44
-347
-819
-1,098
-205
Total liabilities and equity
269
392
1,119
1,624
2,208
1,938
1,706
1,896
1,705
2,899
Shares outstanding
34.2
41.6
50.6
61.9
69.7
70.8
73.1
75.7
77.7
81.5
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-142
-79
-128
-252
-438
-524
-559
-627
-363
683
Depreciation and amortization
3.29
17.7
26.1
32.2
43.5
64.1
129
237
75.7
38.8
Stock-based compensation
35
30.6
33.3
42.1
70.3
104
110
102
74.6
74.5
Deferred income tax
-0.2
0.2
0
8.83
5.87
0.38
-34.3
-46.9
-55.9
-0
Change in receivables
-14.8
-12.2
-29.6
11.5
-10.5
-45
-48.5
-1.54
1.73
-10.2
Change in inventory
0
-6.45
-5.82
-3.46
1.84
1.8
-6.67
-8.18
6.16
-53.9
Change in payables
4.26
24
43.9
26.8
72
45.7
27.5
48.3
-33.3
71.7
Cash from operations
-104
-10.1
-27.6
-98.6
-194
-251
-357
-158
-108
711
Capital expenditures
-1.78
-3.1
-7.1
-13.8
-17.8
-28.2
-32
-28.4
-6.5
-8.86
Acquisitions
0
0
-48.9
0
Purchases of investments
-85.4
-81.4
-68.6
-494
-1,440
-333
-52.8
-174
-608
-1,364
Sales and maturities of investments
192
175
90.4
156
944
843
405
21.5
550
784
Cash from investing
104
13.1
-42.6
-387
-562
219
290
-177
44.2
-862
Debt repaid
0
Stock issued
0
0
118
324
28.1
17.3
14.6
24
28.6
93.1
Cash from financing
0.97
44.2
132
613
669
20.9
168
646
256
331
Exchange rate effect
-1.58
6.2
-3.61
-1.3
7.69
-7.82
Net change in cash
0.3
53.5
57.7
126
-79.2
-19.1
98.7
314
185
203
Free cash flow
-105
-13.2
-34.7
-112
-212
-280
-389
-187
-114
702
Interest paid
4.51
6.27
7.77
7.69
9.8
9.59
18.5
36.1
5.82
5.7
Income taxes paid
0.94
1.1
1.58
2.11
26.4
7.71
4.92
14.2
17.6
36.9
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $62.67 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
12.5%
Operating income / revenue.
EBITDA margin
17.9%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-6.6%
Pre-tax income / revenue.
Net margin
-3.8%
Net income / revenue.
FCF margin
-3.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-3.0%
Cash from operations / revenue.
Return on assets (ROA)
-1.2%
Net income / average total assets.
R&D / revenue
43.0%
Research and development expense / revenue.
SG&A / revenue
34.5%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
8.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.9%
Capital expenditures / revenue.
D&A / revenue
5.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
114.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
35.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
35.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
70.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
19.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
5.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
14.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
7.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
6.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.39x
Current assets / current liabilities.
Quick ratio
3.20x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.89x
(Cash + short-term investments) / current liabilities.
Debt / assets
18.2%
Total debt / total assets.
Liabilities / assets
105.1%
Total liabilities / total assets.
Net debt
-$1.64B
Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA
-9.06x
Net debt / EBITDA (twelve months), when EBITDA is positive.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$10.96
Revenue / diluted weighted shares.
FCF per share
-$0.43
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.33
Cash from operations / diluted weighted shares.
Book value per share
-$1.98
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
5.19x
Market cap / revenue.
EV/Sales
3.56x
Enterprise value / revenue.
EV/EBIT
28.6x
Enterprise value / operating income, when both are positive.
EV/EBITDA
19.9x
Enterprise value / EBITDA, when both are positive.
FCF yield
-0.8%
Free cash flow / market cap.
Earnings yield
-0.7%
Net income / market cap (the inverse of P/E).
What was PTC THERAPEUTICS, INC.'s revenue in fiscal 2025?
PTC THERAPEUTICS, INC. reported revenue of $1.73B for fiscal 2025, 114.5% higher than the year before.
Was PTC THERAPEUTICS, INC. profitable in fiscal 2025?
Yes. Net income was $682.6M, a net margin of 39.4%.
How much free cash flow did PTC THERAPEUTICS, INC. generate in fiscal 2025?
Cash from operations of $711.2M minus capital expenditures of $8.9M left free cash flow of $702.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.